Skip to content
The People's CodeSearch
Menu

H.R. 679 · House bill · 119th Congress

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.

  1. Introduced
  2. In committeeEnergy and Commerce
  3. Passed the House (not yet)
  4. Passed the Senate (not yet)
  5. Law (not yet)

What it says

About this text

Text: , (the only version so far)

Official text on Congress.gov

This bill creates or directs, rather than amending the Code.

Its own words follow, as Congress.gov publishes them.

Sec. 1. Nullification of modifications to REMS for mifepristone

(a) Nullification The modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone are hereby nullified.

(b) No substantially similar provisions The Secretary of Health and Human Services (or any head of any office, department, or agency of the Department of Health and Human Services) shall not establish, implement, or enforce any provision of a risk evaluation and mitigation strategy under section 505–1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355–1) for mifepristone that is substantially similar to any of the modifications nullified by subsection (a).